Abstract:2531 Background: TST005 is a novel bi-functional fusion protein combining a high affinity PD-L1 mAb and a differentiated TGF-β trap with improved stability. In pre-clinical study, TST005 showed no antibody-dependent dependent cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) activity. Methods: This is a Phase 1, dose escalation study with classic 3+3 design to evaluate the safety, tolerability, PK and pharmacodynamic and preliminary anti-tumor activity of TST005 and determine the maximum tolerated dose and/or the Recommended Phase 2 Dose (RP2D). Eligible solid tumor patients who have failed prior standard therapy(ies) and have received no more than one prior immune checkpoint inhibitor (ICI) treatment will be enrolled to receive TST005 intravenous (IV) infusion every 3 weeks until disease progression assessed by the Investigator per RECIST v1.1 and/or immune RECIST, or unacceptable toxicity. Results: The study is ongoing at 4 clinical centers in US and China. As of 31 Jan 2023, 18 eligible subjects have been enrolled into different TST005 dose levels: 2 at dose of 1mg/kg, 4 at 3 mg/kg, 4 at 10 mg/kg, 3 at 20 mg/kg, and 5 at the last dose level of 30 mg/kg. The enrollment is still ongoing. No DLT was observed so far. The most common treatment-emergent adverse events (TEAEs) ( > 10%) included: fatigue (38.9%), rash (22.2%), anemia (16.7%), myalgia (16.7%), and arthralgia, dehydration diarrhea, dry skin, hematuria, hypokalemia, pruritus, lymphocyte count decreased were 11.1%. 7 patients (38.9%) experienced ≥Grade 3 (G3) TEAEs according to CTCAE V5.0, 1 of whom were considered as related to TST005: it was an infusion related reaction (G3), and caused discontinuation of treatment. Two subjects experienced IRRs (G2 and G3 respectively), both at the dose of 3mg/kg cohort. One subject of 30mg/kg dose cohort presented a squamous cell carcinoma of skin, which is known as a classic side effect of TGF-β directed therapies. The subject was discontinued from study and to receive resection. No treatment-related deaths occurred. TST005 demonstrated a nonlinear PK profile between 1 to 20 mg/kg with calculated t1/2 of 4-9 days. ADA was observed in most ADA evaluable subjects, PK at doses ≥ 10mg/kg were not impacted by ADA. At 20mg/kg, the receptor occupancy increased to > 90% immediately after infusion and remain at this level up to C2D1. Start from 1mg/kg, serum TGF-β1 was depleted immediately after dosing, sustained to next dose of TST005. 11 subjects had at least one post treatment tumor assessment per RECIST 1.1. 7 subjects (63.6%) had best overall response of SD. No PR or CR had been observed. Conclusions: TST005 monotherapy demonstrated a good safety and tolerability, nonlinear PK characteristics and significant target engagement in patients with advanced solid tumors. Continue investigation of TST005 as monotherapy or in combination with other therapies are warranted. Clinical trial information: NCT04958434 .

Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody TQC2731 targeting thymic stromal lymphopoietin (TSLP) in healthy Chinese adults.

Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study

565 – Safety and pharmacokinetic profiles of a humanized monoclonal antibody TQH2722 targeting interleukin 4 receptor alpha (IL-4Rα) in health adult subjects

A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects

Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers

P633 First-in-Human Pharmacokinetic and Safety Study of an Anti-TL1A Antibody, TEV-48574, in Healthy Volunteers and Asthma Patients

Phase 1 Safety and Pharmacokinetics Study of TAVO101, an Anti-Human Thymic Stromal Lymphopoietin Antibody for the Treatment of Allergic Inflammatory Conditions

P1061 TEV-48574, an anti-TL1A antibody in development for use in IBD, is safe and well tolerated following 16 weeks of subcutaneous treatment in adults with severe uncontrolled T2-low/non T2 asthma

Tolerability, safety, and pharmacokinetics of a single intravenous administration of a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody in healthy Chinese volunteers

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers

Comparison of the Efficacy and Safety of the Adalimumab Biosimilar TQ-Z2301 and Adalimumab for the Treatment of Chinese Patients with Active Ankylosing Spondylitis: a Multi-Center, Randomized, Double-Blind, Phase III Clinical Trial

Pharmacokinetics, Safety, and Immunogenicity of Intravenous and Subcutaneous Single-Dose QX002N Injection in Healthy Subjects: A Randomized, Open, Parallel, Single-Center, Phase I Study

A Phase 1, First-in-human, Open-Label, Dose Escalation and Dose Expansion Study of TST005 in Patients with Locally Advanced or Metastatic Solid Tumors

The roles of thymic stromal lymphopoietin receptor and its antibody in airway inflammatory response in asthmatic mice

Pharmacokinetics and immunogenicity of T0001, a newly developed anti-TNFα fusion protein, in healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants With Chronic Rhinosinusitis With Nasal Polyps, and Participants With Atopic Dermatitis: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study

Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors

LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects

Safety And Tolerability Of A Single Dose T0001 In Chinese Healthy Adult Volunteers: A First-In-Human Ascending Dose Study

Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects